Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria - all subjects must:~1. Be at least 18 years of age~2. Subjects must have a documented diagnosis of MM and have either refractory or relapsed and refractory after first line treatment disease defined as:~   * Primary refractory~  * Refractory~  * Relapsed and Refractory~3. Subjects must have undergone prior treatment with one treatment line of anti-myeloma therapy. Induction therapy followed by ASCT and consolidation/maintenance will be considered as one line.Have a confirmed diagnosis of MM~4. Have received lenalidomide after one prior treatment for MM and have reached at least a partial response (PR), according to IMWG criteria, including two consolidating cycles. Subjects have experienced a response at least PR after starting treatment with lenalidomide and cortisone cycles.~5. Have personally signed and dated a legally effective written informed consent form prior to admission to the study.~6. Must be willing and able to understand and comply with the study requirements.~7. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception.~8. Male must agree to practice contraception~Exclusion Criteria:~1. Any of the following laboratory abnormalities:~   * Absolute neutrophil count (ANC) \< 1,000/µL~  * Platelet count \< 75,000/ µL~  * Creatinine Clearance \< 45 mL/min according to Cockcroft-Gault formula~  * Serum SGOT/AST or SGPT/ALT \> 3.0 x upper limit of normal (ULN)~  * Serum total bilirubin \> 2.0 mg/dL~2. ECOG performance status \<4.~3. Individuals who have had a stem-cell transplant as a 2nd line treatment for MM~4. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.~5. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.~6. Pregnant or lactating females.~7. Any other clinically significant medical disease or condition that, in the Investigator´s opinion, may interfere with protocol adherence or a subject´s ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Revlimid (Type: EXPERIMENTAL): None
- Revlimid and dexamethasone (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).